Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

13 Dec 2016

Abstract excerpt

Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations in human cancer, but therapeutic approaches that target these defects are not yet clinically available. We demonstrate that defects in ARID1A sensitize tumour cells to clinical inhibitors of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chromatin Remodeling and Cancer
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27958275
DOI: 10.1038/ncomms13837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1APMID 27958275Read ↗

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage responseSemantic proximity Read ↗

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsSemantic proximity Read ↗

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient MalignanciesSemantic proximity Read ↗

Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapySemantic proximity Read ↗

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapySemantic proximity Read ↗

ATM and ATR as therapeutic targets in cancerSemantic proximity Read ↗

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancersSemantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategiesSemantic proximity Read ↗

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers.Semantic proximity Read ↗

Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stressSemantic proximity Read ↗

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.